Core Viewpoint - Shanghai Laishi (002252) reported that as of October 10, 2025, the total number of shareholders is 110,316 [1] Summary by Relevant Sections - Company Information - The total number of shareholders for Shanghai Laishi is 110,316 as of the specified date [1]

Core Viewpoint - Shanghai Laishi (002252) has shown a positive trend in financing activities, with a net buying of 3.64 million yuan on October 16, 2025, and a total net buying of 14.29 million yuan over the last three trading days [1][2]. Financing Activities - On October 16, 2025, the financing buy-in was 42.58 million yuan, while the financing repayment was 38.94 million yuan, resulting in a net buy of 3.64 million yuan [1]. - The financing balance reached 1.288 billion yuan, with 13 out of the last 20 trading days showing net buying activity [1][2]. - The financing balance as of October 16, 2025, represented 2.89% of the circulating market value [2]. Margin Trading Activities - On the same day, there was a short selling of 14,000 shares, with a net sell of 10,400 shares after repaying 3,600 shares [2][3]. - The margin trading balance was reported at 4.8554 million yuan, with a total of 723,600 shares remaining in the short selling account [3]. Overall Margin Trading Balance - The total margin trading balance was 1.293 billion yuan on October 16, 2025, reflecting an increase of 3.69 million yuan or 0.29% from the previous day [4]. - The margin trading balance has shown fluctuations, with a notable decrease of 12.25 million yuan on October 13, 2025 [4].

Core Viewpoint - The company is actively advancing the resumption of production at Guangxi Laishi, with all activities progressing according to the disclosed plans and arrangements. Currently, Guangxi Laishi is in the trial production phase [1] Group 1 - The company is focusing on the resumption of operations at Guangxi Laishi [1] - Production activities are proceeding as per the previously disclosed plans [1] - Guangxi Laishi is currently undergoing trial production [1]

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. announced the progress of its share repurchase plan on October 10, 2025 [1] - The repurchase plan was approved on January 13, 2025, with a total fund of no less than 250 million yuan and no more than 500 million yuan, with a maximum repurchase price of 9.55 yuan per share [2] - As of the end of September 2025, the company had repurchased a total of 70,974,175 shares at a minimum price of 6.62 yuan per share, with a total transaction amount of approximately 469.85 million yuan [3] Group 2 - The company confirmed that the repurchase complies with the established plan and relevant legal regulations, ensuring that no major events affecting the stock price occurred during the repurchase period [4] - The company will continue to advance the repurchase plan based on market conditions and will fulfill information disclosure obligations as required [4]

Group 1 - The company Shanghai Laishi (SZ 002252) announced on October 9 that it has repurchased approximately 68.32 million shares, accounting for 1.03% of its total share capital, with a total transaction amount of about 470 million yuan [1][1][1] - The highest transaction price during the share buyback was 7.09 yuan per share, while the lowest was 6.62 yuan per share [1][1][1] - As of the report, Shanghai Laishi's market capitalization stands at 45 billion yuan [1][1][1] Group 2 - For the first half of 2025, the company's revenue composition shows that blood product production and sales accounted for 99.21%, while testing equipment and reagents made up 0.76%, and other businesses contributed 0.03% [1][1][1]

Core Viewpoint - Shanghai Laishi (002252.SZ) has announced a share buyback program, indicating a commitment to returning value to shareholders through the repurchase of its own shares [1] Summary by Categories Share Buyback Details - The company has repurchased a total of 68,321,952 shares, which represents 1.03% of its total share capital [1] - The highest transaction price during the buyback was 7.09 CNY per share, while the lowest was 6.62 CNY per share [1] - The total amount spent on the buyback reached 469,849,037.98 CNY, excluding transaction commissions and other fees [1]

证券代码：002252 证券简称：上海莱士 公告编号：2025-064 上述回购符合公司既定回购股份方案及相关法律法规的要求。 上海莱士血液制品股份有限公司（"公司"）于 2025 年 1 月 13 日召开了第六 届董事会第七次（临时）会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有或自筹资金以集中竞价交易方式从二级市场回购公司股份，用 于实施员工持股计划或股权激励，拟回购股份的资金总额为不低于人民币 2.5 亿 元（含）且不超过人民币 5 亿元（含），拟回购股份价格不超过人民币 9.55 元/ 股（含），具体回购股份数量以回购股份方案实施完毕或回购实施期限届满时实 际回购情况为准。回购期限自股东大会审议通过本次回购股份方案之日起 12 个 月内，如果触及回购股份方案提及的相关条件时，回购期限提前届满。公司于 2025 年 2 月 14 日召开 2025 年第一次临时股东大会审议通过了上述股份回购方 案。具体内容详见公司分别于 2025 年 1 月 14 日、2025 年 2 月 15 日在《证券时 报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资讯网（www.cninfo.com ...

Group 1 - The company Shanghai Laishi (002252.SZ) has completed the enrollment of all patients for the IIb clinical trial of SR604 injection, which is aimed at the prevention of bleeding episodes in patients with Hemophilia A/B and congenital factor VII deficiency [2] - The company expects to complete the trial work in the first half of next year [2]

Core Insights - Shanghai Laishi (002252) reported that as of September 19, 2025, the total number of shareholders is 109,859 [1] Company Summary - The company has a total of 109,859 shareholders as of the specified date [1]

Core Viewpoint - Shanghai Laishi's stock price has underperformed the market despite multiple buyback and shareholding increase plans, with a significant decline in revenue and net profit in the first half of the year [1][5]. Stock Performance - As of September 22, Shanghai Laishi's stock closed at 6.75 yuan per share, marking a continuous decline for four trading days [2]. - Year-to-date, the stock has dropped by 5.72%, while the broader market has increased by 33.1% [2]. Shareholding and Buyback Plans - The controlling shareholder, Haiyingkang, completed a shareholding increase plan, acquiring 72.9353 million shares, representing 1.1% of the total share capital, with a total investment of approximately 500 million yuan [2][3]. - Company executives, including the vice chairman and several vice presidents, plan to increase their holdings by at least 6 million yuan over the next six months [3]. - The company has also repurchased 68.322 million shares, accounting for 1.03% of the total share capital, with a total expenditure of 470 million yuan [3]. Financial Performance - In the first half of the year, Shanghai Laishi reported revenue of approximately 3.952 billion yuan, a year-on-year decrease of 7.06%, and a net profit of about 1.03 billion yuan, down 17% [5]. - The decline in revenue is attributed to policy impacts and supply-demand dynamics affecting the sales of albumin and immunoglobulin products [5]. Market Position and Future Outlook - Despite short-term performance challenges, Shanghai Laishi maintains a strong position in the blood products industry, with plans to expand its product line and increase the number of plasma collection stations [6]. - The company is also exploring growth opportunities through strategic initiatives, although it faces significant market competition and industry changes [6].